BioCurex Inc. Announces its Scientific Advisory Board.

Business Editors & Health/Medical Writers

RANCHO SANTA MARGARITA, Calif.--(BW HealthWire)--May 9, 2001

Dr. Ricardo Moro, president and Dr. Gerald Wittenberg, chairman are pleased to announce the members of BioCurex's Scientific Advisory Board.

Phil Gold, C.C., O.Q., M.D., Ph.D.

Dr. Gold attended McGill University where he obtained four degrees. His Ph.D.degree thesis title was "Carcinoembryonic Antigens (CEA) of the Human Digestive System" which, along with the description of alpha-fetoprotein (AFP), ushered in the modern era of human tumor marker research along with the diagnostic ramifications that this work has had over the past quarter century.

The essay for CEA developed by Gold, has become the most used marker for human cancer diagnosis and monitoring. Most recently, in experimental attempts to eradicate tumors with monoclonals, anti-CEA antibodies have been used as a homing device for cancer cell cytotoxic agents.

In recognition of the scientific contributions made by Gold, he has been the recipient of numerous international awards and honors that are too numerous to mention here. He currently is the physician-in-chief, department of medicine at The Montreal General Hospital; Douglas G. Cameron, professor of medicine, McGill University; professor, departments of physiology and oncology, McGill University and the director of the McGill University Medical Clinic at the Montreal General Hospital.

Dr. Garri Abelev Ph.D., M.D.

In 1963, Dr. Abelev and his colleagues first described the association between alfa-fetoprotein (AFP) and liver cancer. This was the first cancer marker of clinical use ever reported. His work launched the entire field of tumor markers into the multi-billion dollar industry it is today and he is considered the dean of the cancer marker community. Abelev has contributed in very significant ways to the understanding of the functions of AFP. He continues his work in a very active way in his laboratory at the Cancer Research Center, immunochemistry division in Moscow.

Jose Uriel, M.D., Ph.D.

Dr. Uriel has worked at the Pasteur Institute and was research director of the prestigious CNRS. He also worked at the Laboratory of Immunology, NIH Bethesda, Md. From 1963 to 1995, he directed the laboratory of protein chemistry at the French Research Cancer Institute of which he was later the director.

In 1970 he received the prestigious Rosen Award in cancer research and in 1972 became laureate of the French National Academy of Medicine (Leon Berat Prize). Uriel has published more than 220 scientific papers and written several chapters in books related to cancer research. Uriel has made major contributions to the understanding of the physiology of AFP and cancer markers.

Maria Jose Villacampa, Ph.D.

Dr. Villacampa is a full professor at the department of biochemistry and cellular and molecular biology at the University of Zaragoza in Spain. She was part of the team which initially characterized RECAF and has published a significant number of papers related to the different aspects of this molecule in collaborations with Uriel and Moro.

Taiki Tamaoki, Ph.D.

Dr. Tamaoki obtained his degree in 1960 at the University of Wisconsin. He moved to the University of Alberta, cancer research unit where he worked as associate professor and then faculty professor at the University of Calgary. He held positions as research associate of the National Cancer Institute of Canada and at Terry Fox Cancer Research Institute. Tamaoki is a molecular biologist and it was in his laboratory that alpha-fetoprotein (AFP) was cloned for the first time. His paper was published in the prestigious journal, Proceedings of the National Academy of Sciences. He is regarded as the worldwide authority in AFP structure.

Elliot Alpert Ph.D.

Dr. Alpert is one of the pioneers in the field of AFP and cancer markers. He has made significant contributions to this field. A member of the New York Academy of Sciences, Alpert is in charge of the workshop for evaluation of cancer markers for the International Society of Onco developmental biology and medicine.

Michel Sadelain, M.D., Ph.D.

Dr. Sadelain is director of one of the handful of gene therapy units approved by the FDA in the United States. The laboratory he manages is actively involved in genetic engineering applied to the immune system, a combination of fields that will prove valuable for future work on RECAF. Sadelain has previously worked together with Moro using RECAF in experiments showing complete abrogation of tumor growth in animal models.

"We are very pleased to have these highly respected scientists guide BioCurex Inc. in its mission to become an integrated biotechnology company with expertise in cancer diagnostics, imaging and therapeutics. Their contributions have been significant and we look forward to their further input in the development of our RECAF technology," said Wittenberg.

BioCurex Technologies Inc. is a biotechnology company that has developed patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics.

The technology identifies a universal cancer biomarker or receptor known as RECAF, thereby allowing detection of malignant cancers from blood tests or tissue biopsies. The cancer diagnostics market is presently estimated at $4 billion. The technology can also be used to image the location of the cancer and improve the present detection systems.

Accurate and timely diagnosis is the vital first stem in managing cancer and it is projected that BioCurex can obtain a leadership position in the screening, diagnosis and imaging of cancer. Initial results indicate that this technology can detect more than 90% of all cancers in blood or tissue samples.

Forward-looking statements contained in this news release are made under the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995. Any such statements are subject to risks and uncertainties that could cause actual results of events to differ materially from those anticipated in such forward-looking statements.